A Phase 4 interventional study of Cervical cerclage and Vaginal progesterone in Premature Birth, sponsored by Thomas Jefferson University. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by Thomas Jefferson University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Premature Birth with a site in Italy — 28 open to participants now, 31 under way, none of them phase 3. Premature Birth · Italy.
Among the 120 studies in Premature Birth with a site in Italy, this one is the 45th largest by enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2017, is one of 7 in phase 4, and was the 47th registered.
2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.
Browse Premature Birth studies →28 of the 120 studies in Premature Birth with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy
Ages 24 wk–30 wk
University of Roma La Sapienza · Sites in Italy
Ages 18+ · Women only
Fabrizio Faina · Sites in Italy
Ages 5 days–15 days
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 26 wk–32 wk
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 18 · Phase 4 7
First in 1999; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 100 across the 82 interventional studies, 78 across the 38 observational. Of the 54 that completed or were terminated, 7 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 120 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 8 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
7 of the studies in Premature Birth with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07633184Azienda USL Reggio Emilia - IRCCSLung Ultrasound Score for Early Prediction of Bronchopulmonary Dysplasia in Preterm Newborns | 2027-02 |
| NCT06919757Fondazione Policlinico Universitario Agostino Gemelli IRCCSEarly Lung Function Trajectories: Comparison Between Infants With and Without Intrauterine Growth Restriction. | 2027-03 |
| NCT07305519University of Roma La SapienzaThe Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth: | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 120 studies in Premature Birth with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the efficacy of cervical cerclage in prevention of spontaneous preterm birth in singleton pregnancies with a short transvaginal cervical length (\<=25mm) and without prior spontaneous preterm birth
Singleton pregnancies between 18 0/7 to 23 6/7 weeks without a prior spontaneous preterm birth found to have a short transvaginal ultrasound cervical length (\<=25mm) and meeting all other eligibility criteria will be randomized to either cervical cerclage or control (no cerclage). Aside from cerclage placement, management of included women will be the same including recommendation for daily vaginal progesterone 200mg suppository or 90mg gel from randomization until 36 6/7 weeks. The primary outcome will be the incidence of spontaneous preterm birth \<35 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
Procedure: Cervical cerclage · Drug: Vaginal progesterone
Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
Drug: Vaginal progesterone
Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Preterm birth <35 weeks
Incidence of spontaneous preterm birth less than 35 weeks
Time frame: At delivery
Preterm birth <37 weeks, <34 weeks, <32 weeks, <28 weeks, <24 weeks
Time frame: At delivery
Mean gestational age at delivery
Time frame: At delivery
Histologically proven clinical chorioamnionitis
Time frame: At delivery
Neonatal outcomes: birth weight
Time frame: At delivery
Neonatal outcomes: low birth weight (<2500g),
Time frame: At delivery
Neonatal outcomes: admission to intensive care nursery
Time frame: At delivery
Neonatal outcomes: length of neonatal hospital admission
Time frame: at least 30 days after delivery, up to 6 months after delivery
Neonatal outcomes: respiratory distress syndrome
Time frame: at least 30 days after delivery, up to 6 months after delivery
Neonatal outcomes: IVH grade 3 or 4
Time frame: at least 30 days after delivery, up to 6 months after delivery
Neonatal outcomes: retinopathy of prematurity
Time frame: at least 30 days after delivery, up to 6 months after delivery
Neonatal outcomes: bronchopulmonary dysplasia
Time frame: at least 30 days after delivery, up to 6 months after delivery
Neonatal outcomes: neonatal mortality
Time frame: 28 days after delivery
Plan to share: Yes — IPD will be shared upon completion of appropriate data sharing agreements
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 1yr after study completion
Access criteria: IPD will be shared upon completion of appropriate data sharing agreements
Ran from Sep 2017 to primary completion in Feb 2024, 76 months.
Of 54 non-industry phase 4 interventional studies under Premature Birth, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's 76 months is above that.
Counting every sponsor, half of 54 studies reached it within 25 months; a quarter within 13 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.